… molecular targeted therapy according to the drive gene … population groups in non-small
cell lung cancer (NSCLC) have … factor receptor mutations and lymphoma kinase gene fusion …

… leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive
non-small cell lung cancer … or overexpression of the HER2 gene, resulting in its dysfunction. …

… gene have recently been described in multiple malignancies, … non-small cell lung cancer
(NSCLC). ROS1 rearrangement defines a new molecular subset of NSCLC with the prevalence …

… 肺癌是最常见的恶性肿瘤，非小细胞肺癌（non-small cell lung cancer, NSCLC）发生率约占
所有肺癌的85%。人表皮生长因子受体2（human epidermal growth factor receptor-2, HER2）是…

… tumor (>3 cm). This part of our study provided a clinical reference in targeted therapy screening
with non-small cell lung cancer … FGFR gene alterations in lung squamous cell carcinoma …

… death ligand 1, PD-L1）免疫抑制剂为代表的免疫疗法很大程度地改变了非小细胞肺癌（non-small
cell lung cancer, NSCLC）的治疗现状。目前PD-L1已经成为了筛选NSCLC免疫治疗获益…

… KRAS long defined as a “non⁃druggable target”. The deeper … Molecular epidemiology of
EGFR and KRAS mutations in … of KRAS mutations in advanced non⁃small cell lung cancer [J]…

… subsets in patients with non-small cell lung cancer (NSCLC). … Molecular Epidemiology of
the Main Druggable Genetic … renal disorders of erlotinib in patients with non-small-cell lung …

… molecular characteristics in lung cancer and aim to provide the direction and basis for future
research. Key words: Lung cancer; Molecular genetic … mutations of small-cell lung cancer[J]. …

… However,the development of targeted drugs against KRAS gene mutations has failed,and …
抑制剂,用于治疗非小细胞肺癌(nonsmall cell lung cancer,NSCLC)及结直肠癌成人患 者.目前有…